{"pub_date": "2016-09-16T07:30:34+0000", "subsection_name": null, "lead_paragraph": "Inclusion on a federal list would mean Mylan could keep its list price high \u2014 or even raise it \u2014 without patients\u2019 complaining. But consumers would feel it indirectly.", "print_page": "1", "document_type": "article", "byline": {"contributor": "", "person": [{"rank": 1, "organization": "", "lastname": "LIPTON", "firstname": "Eric", "role": "reported"}, {"rank": 2, "organization": "", "lastname": "ABRAMS", "firstname": "Rachel", "role": "reported"}], "original": "By ERIC LIPTON and RACHEL ABRAMS"}, "multimedia": [{"width": 190, "height": 126, "url": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-thumbWide.jpg", "subtype": "wide", "legacy": {"wide": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-thumbWide.jpg", "widewidth": "190", "wideheight": "126"}, "type": "image"}, {"width": 600, "height": 391, "url": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-articleLarge.jpg", "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "391", "xlarge": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-articleLarge.jpg"}, "type": "image"}, {"width": 75, "height": 75, "url": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-thumbStandard.jpg", "subtype": "thumbnail", "legacy": {"thumbnail": "images/2016/09/16/business/16epipenlobby-1/16epipenlobby-1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image"}], "section_name": "Business Day", "headline": {"print_headline": "Tactic by Maker of EpiPen Could Quell Protests", "main": "EpiPen Maker Lobbies to Shift High Costs to Others"}, "source": "The New York Times", "blog": [], "word_count": "2082", "web_url": "http://www.nytimes.com/2016/09/16/business/epipen-maker-mylan-preventative-drug-campaign.html", "slideshow_credits": null, "news_desk": "Business", "type_of_material": "News", "snippet": "Inclusion on a federal list would mean Mylan could keep its list price high \u2014 or even raise it \u2014 without patients\u2019 complaining. But consumers would feel it indirectly....", "_id": "57db9f9f95d0e021d7986943", "abstract": null, "keywords": [{"rank": "1", "name": "organizations", "value": "Mylan Inc", "is_major": "Y"}, {"rank": "2", "name": "subject", "value": "Epinephrine (Drug)", "is_major": "Y"}, {"rank": "3", "name": "subject", "value": "Lobbying and Lobbyists", "is_major": "N"}, {"rank": "4", "name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N"}, {"rank": "5", "name": "subject", "value": "Law and Legislation", "is_major": "N"}, {"rank": "6", "name": "subject", "value": "Health Insurance and Managed Care", "is_major": "Y"}, {"rank": "7", "name": "organizations", "value": "United States Preventive Services Task Force", "is_major": "N"}]}